← Eichor
Study identifier: NCT06262776 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Safety and Immunogenicity of Recombinant Zoster Vaccine for Transplant Recipients

Condition: Immunosuppression · Vaccine Response Impaired  ·  Sponsor: Central Adelaide Local Health Network Incorporated

PhaseNA
Planned participants160
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The goal of this clinical trial is to compare responses to Varicella Zoster vaccination between transplant patients on different medication regimens, and their healthy co-habitants. The main questions it aims to answer are: 1. Are there differences in vaccination immunological responses in transplant patients on different immunosuppression regimens? 2. Are there differences in vaccination immunological responses between transplant patients and their healthy co-habitants? Participants will all receive a 2-dose course of SHINGRIX recombinant Zoster vaccination, and have immunological responses measured and compared at 5 timepoints between 1 week to 1 year post-vaccination.

This description comes directly from the study's public registry record.

Talk to the study team

Patrick T Coates, MBBS, FRACP, PhD  ·  70740000  ·  Toby.Coates@sa.gov.au

Griffith B Perkins, PhD  ·  70740000  ·  Griffith.Perkins@adelaide.edu.au

Always discuss trial participation with your own doctor first.

Locations (1)

Royal Adelaide HospitalAdelaide, South Australia, AustraliaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06262776